Core Insights - Binah Capital reported a significant turnaround in its financial performance for Q4 2025 and the full year, indicating a positive growth trajectory for the company [2][4]. Q4 Results - Binah Capital's Q4 revenue reached $50.5 million, a 13.2% increase year-over-year [2]. - Gross profit improved to $10.3 million from $8.9 million in the previous year [2]. - The company achieved a GAAP net income of $0.2 million, recovering from a loss of $1.1 million in Q4 2024 [2]. - GAAP diluted earnings per share were $0.01, up from a loss of $0.07 per share in the same quarter last year [3]. - EBITDA for Q4 declined to $0.5 million from $1.0 million, primarily due to changes in the income tax provision [3]. Full-Year 2025 Performance - For the full year, revenue increased by 10.7% to $187.1 million [4]. - GAAP net income reached $2.3 million, reversing a loss of $4.6 million in 2024 [4]. - Annual EBITDA rose to $5.4 million, up from $1.9 million the previous year [4]. - Total advisory and brokerage assets grew by 11% to $29.9 billion as of December 31, 2025 [4]. Management Commentary - Craig Gould, CEO of Binah Capital, attributed the company's growth to its "differentiated platform" and highlighted the potential for continued growth in 2026 [5]. Trading Metrics - Binah Capital has a market capitalization of $33.37 million, with stock trading between $1.36 and $3.44 over the past year [6]. - The Relative Strength Index (RSI) stands at 44.18, indicating a neutral position [6]. - Over the past 12 months, the stock has gained 4.15% and is currently 31.3% above its 52-week low [6]. Price Action - The stock closed at $2.01, down 1.95% in the latest trading session, with a negative price trend indicated across all time frames [7].

Core Viewpoint - Alto Ingredients Inc is experiencing a significant stock surge following a strong earnings report, indicating a successful turnaround for the renewable fuels producer [1]. Financial Performance - Adjusted EBITDA for Q4 increased to $27.9 million from a negative $7.7 million, driven by improved crush margins, renewable fuel export sales, and derivative gains [2]. - For 2025, the company reported a net income of $12.1 million, or 16 cents per share, compared to a loss of $60.3 million in 2024, and generated $44.7 million in adjusted EBITDA [2]. Strategic Positioning - CEO Bryon McGregor stated that the company entered 2026 in a stronger position, focusing on enhancing production capabilities, increasing exports, monetizing Section 45Z tax credits, and capitalizing on rising demand for liquid CO2 [3]. - At the end of 2025, the company had $23.4 million in cash and $102 million in borrowing availability, providing flexibility for growth initiatives [3]. Stock Performance - Over the past year, Alto's shares rose from approximately $0.78 to a new 52-week high near $3.86, with the latest earnings-driven spike extending a strong rally from late 2025 [4]. - The stock is currently trading well above its 20-, 50-, and 200-day moving averages, indicating strong upward momentum [4]. Market Reaction - Alto Ingredients shares surged by 50.38% to $3.92 at the time of publication, marking a new 52-week high according to Benzinga Pro data [5].

Core Insights - Sealed Air reported a net earnings of $44 million for Q4 2025, a significant recovery from a net loss of less than $1 million in the same period last year [1] - The company's net sales increased by 2% to $1.4 billion, with the protective segment growing by 3% and the food segment by 2% [1] - The company is set to go private in an acquisition by CD&R, valued at $10.3 billion, with stockholders receiving $42.15 per share [4] Financial Performance - Adjusted EBITDA for Q4 reached $278 million, representing 19.8% of net sales, compared to $271 million or 19.7% of net sales in the previous year [2] - For the full year 2025, Sealed Air's net sales totaled $5.36 billion, a slight decrease of less than 1% from 2024, while full-year net earnings rose to $441 million from $270 million in 2024 [5] - Adjusted EBITDA for the full year was reported at $1.1 billion, representing 21.2% of net sales [5] Segment Performance - Food segment sales for Q4 were $937 million, a 2% increase from the previous year, with currency impacts contributing a positive $28 million [3] - Protective segment sales totaled $464 million, up 3%, including a favorable currency impact of $10 million [3] - The improvement in overall performance was attributed to reduced operating costs from productivity gains and favorable currency effects, despite challenges in net price realization and lower food segment volumes [3] Acquisition Details - The acquisition by CD&R was agreed upon in November 2025, with stockholder approval obtained at a special meeting last month [4] - The transaction is expected to close in mid-2026, pending regulatory approvals and customary closing conditions [4]

Core Insights - Oscar Health Inc. reported fourth-quarter revenue of approximately $2.81 billion, missing the consensus estimate of $3.12 billion, while total revenue for fiscal 2025 reached approximately $11.7 billion, up from $9.2 billion a year ago, driven by higher membership [1] - The medical loss ratio increased to 95.4% for the quarter from 88.1% a year ago, primarily due to higher average market morbidity and increased utilization [2] - The company reported a loss of $1.24 per share, missing the consensus estimate of 89 cents, while the loss from operations was $333.75 million, up from $147.73 million a year ago [2][4] Financial Performance - The SG&A expense ratio improved to 18.2% from 19.5%, attributed to greater fixed cost leverage and disciplined cost management [3] - Adjusted EBITDA loss for the quarter was $101.5 million, an improvement from a loss of $307.78 million in the previous year [4] - Total membership increased significantly from 1.68 million to 2.04 million in the quarter [4] Strategic Outlook - The CEO stated that 2025 was a reset year for the individual market, with plans to return to profitability in 2026 through new affordable products and enhanced member experience [5] - Oscar Health announced a $475 million three-year revolving credit facility to strengthen its balance sheet and optimize capital structure [6] - The company projects fiscal 2026 sales between $18.7 billion and $19 billion, significantly above Wall Street's estimate of $12.57 billion [7] Guidance - Oscar Health expects a medical loss ratio of 82.4%-83.4% for 2025, an SG&A expense ratio of 15.8%-16.3%, and operating earnings between $250 million and $450 million [8] - Oscar shares rose by 5.60% to $13.39, with a daily high of $14.37 and a low of $13.01 [8]